- $68.66m
- $43.24m
- $0.41m
MediciNova Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Medicinova Presents Study Update And Interim Analysis Of Phase 2/3 Clinical Trial Of Mn-166 (Ibudilast)
MediciNova Inc reports results for the quarter - Earnings Summary
MediciNova Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Medicinova To Support NIH-funded Expanded Access Clinical Trial To Evaluate Ibudilast
MediciNova Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 For Prevention Of Metastasis Of Various Solid Cancer
Brief: MediciNova Announces Data From Phase 1b/2a Clinical Trial Of MN-166 In Glioblastoma Patients
MediciNova Inc reports results for the quarter ended in March - Earnings Summary
MediciNova Inc expected to post a loss of 5 cents a share - Earnings Preview
MediciNova Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: MediciNova Receives A Notice Of Grant For A New Patent Covering Mn-166 (Ibudilast) For The Treatment Of Macular Injury In China
Brief: Medicinova Receives Notice Of Decision To Grant For New Patent Covering Mn-166 (Ibudilast) For Treatment Of Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE-Zoom Video, HP Inc, Boeing
U.S. STOCKS ON THE MOVE-Kohl's, Bristol-Myers Squibb, 2Seventy Bio
U.S. STOCKS ON THE MOVE-MediciNova, PENN Entertainment, Medtronic
MediciNova rises after positive data from mid-stage cancer treatment study
Brief: Medicinova Says MN-166 And TMZ Combination Treatment Was Safe And Well-Tolerated, And No Unexpected Adverse Effects Were Reported
Brief: Medicinova Receives Notice Of Allowance For New Patent For The Treatment Of Amyotrophic Lateral Sclerosis In Canada